Compared with chemotherapy alone, the addition of the anti‐programmed cell death 1 ligand 1 (PD‐L1) antibodies significantly improved the overall survival (OS) of patients with ES‐SCLC both in the IMpower 133 and CASPIAN clinical trials.6, 7. Here, CD274 is linked to small cell lung carcinoma.